HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Includes Cannabinoids Among Nair Bladeless Shave Luxury Treatment Choices

First Response Pregnancy Test Line Extended With Comfort Check

Executive Summary

C&D launching three-product Nair Bladeless Shave line extension, including one with cannabinoids. First Response line Comfort Check extension contains three early tests and five pregnancy strips.

You may also be interested in...



US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements

Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”

Church & Dwight Cuts Outlook Due To Rising Costs, Adds Suppliers To Strengthen ‘Weak Links’

“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel